Gland Pharma Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/rn4824bnhtzhezbq9wdr5aho.pdf

Key Takeaways


Revenue Decline: The Two Big Drivers

Srinivas Sadu: "The assumptions what you made earlier when the product gets emphasized, and what price you go and bid, that's completely different now."

Customer Disruptions & Recovery Actions

Srinivas Sadu: "It could be a temporary impact where supplies of stock because we also need to recover the money. But I think in long run, these can be productive because it is under this process, where if somebody acquires it, they have acquired the contract where they have to pay the cure money and also, they get rights for the GPO contracts where they get transfers."

Margin Walk: Operating Leverage, Not Gross Margin

Srinivas Sadu: "I still feel that it should settle around 10%."

Heparin & Enoxaparin: Price-Driven Headwinds


Cenexi Acquisition & New Capabilities


Competitive Positioning & Long-Term View

Srinivas Sadu: "There could be a temporary issue with us, but in the long run, if the competition is going down, raising the market, so probably we should think that maybe it's going back to 3, 4 years ago where there were lesser competitors with these guys exiting the market."

Guidance & Commitments

CommitmentSpecificsTimeline
Product launches11-12 products launching; 1 this quarter, 3-4 in next 9 monthsNext quarter / next 9 months
Bankrupt customer resolutionSale process completes, clarity on contract ownershipEnd of June
Bankrupt customer business recovery70-80% of ~₹200 cr annual business expected to returnPost-sale process
Penem line commercializationRestarted May 15 with 3 lyophilizers (up from 2)Already operational
Profit share recoveryShould settle around 10%No specific timeline
China approvals3-4 more product approvals expectedDuring the year
Cenexi consolidation2 months (May and June) consolidated in Q1 FY24Q1 FY24
No planned shutdownsNo plant shutdowns planned in the near futureNear future
No incremental P&L costs from new plantsNo incremental cost from plants entering commercializationOngoing

Key Metrics

MetricQ4 FY23
Revenue₹785 cr, down 29% YoY
Full-year revenue₹3,624.6 cr, down 18% YoY
EBITDA₹168.4 cr, down 52% YoY
EBITDA margin21%, vs 32% in Q4 FY22
Full-year EBITDA margin28%, vs 34% in FY22
PAT₹78.7 cr, down 72% YoY
PAT margin10%, vs 22% for full year FY23
Gross profit marginImproved YoY, favourable geography mix
Profit share7% of revenue, vs 8% for full year FY23 and 10–11% historically
R&D expense₹67.8 cr, 8.6% of revenue
Core markets revenue share70% of Q4 revenue, vs 64% in Q4 FY22
Rest of World markets revenue share22% of Q4 revenue, vs 17% in Q4 FY22
India market revenue share8% of Q4 revenue
ANDA filings in the quarter9
Cash and equivalents₹3,770.7 cr as on March 31, 2023
Cash conversion cycle256 days for FY23, vs 180 days at FY22 year-end
Exceptional item: provision for customer bankruptcy₹56.5 cr
Penem line shutdown revenue impact~₹30–40 cr
Heparin and Enoxaparin combined FY23 revenue~₹970 cr, vs ~₹1,200 cr in FY22